Introduction {#sec1}
============

Cytoreductive nephrectomy (CN) in the presence of metastatic disease is a unique feature of the therapeutics of advanced renal cancer (RCC). There are two randomized trials demonstrating the overall survival (OS) benefit favoring CN in metastatic disease compared to systemic interferon therapy alone ([@cit0001], [@cit0002]). The only systemic therapies available previously were cytokine-based regimens such as interleukin and interferon during the time period when these CN trials were conducted. Within the last decade, 10 additional therapies have attained Food and Drug Administration (FDA) approval in metastatic renal cancer ([@cit0003]). Until recently, no prospective study had been completed evaluating the role of CN in the setting of contemporary systemic therapies. The results of two randomized trials comparing CN followed by sunitinib versus systemic therapy with sunitinib followed by CN \[SURTIME trial\] and nephrectomy followed by sunitinib versus sunitinib alone (CARMENA) were recently reported. Both studies indicated that the clinical outcomes with sunitinib alone were at least similar and possibly slightly improved in the metastatic RCC patients randomized to deferred or no CN ([@cit0004], [@cit0005]). The studies showed that CN does not impart additional survival benefit in the setting of effective systemic therapy, and a proportion of patients are deprived of systemic therapy due to complications of CN. In summary, the concept of CN being an essential component of metastatic RCC therapy is being seriously questioned. These data need to be considered in future therapeutic decisions in metastatic RCC.

The National Cancer Database (NCDB), which reflects community-based data from hospitals with Commission on Cancer accreditation, continues to reveal that the incidence of CN in distant-/advanced-stage RCC is seen in about a third of the patients ([@cit0006]). Unlike clinical trials of systemic therapy, where 80--100% of patients are receiving nephrectomy, the majority of the patients in the real-world treatment of RCC are not receiving CN as primary management. The overall survival outcome has improved in advanced RCC; however, it also appears that the patients with CN received the maximum benefit ([@cit0007]). Despite randomized evidence to the contrary, the OS results in SEER show that CN patients have a large magnitude of benefit as compared to non-CN patients. This finding may be confounded by the fact that the patients undergoing CN are probably younger, healthier, and less likely to have aggressive or poor risk disease, factors that portend an improved prognosis regardless of nephrectomy status. In an attempt to overcome the confounding effect of conflicting prognostic factors, we analyzed and reported on a clinical trial population with metastatic disease and found that CN maintained a significant positive impact on clinical outcomes ([@cit0008]).

In the targeted therapy era, we conducted a SEER data analysis of outcomes in patients who have undergone CN versus those who have not undergone CN. The results revealed that only the post-nephrectomy population appeared to benefit from advances in systemic therapies ([@cit0008]). Clearly, an intervention that would increase the possibility of CN in metastatic RCC would likely improve outcomes. The controversy of whether CN should be standard in metastatic RCC continues, with the recent randomized prospective trials suggesting minimal contribution of CN in improving outcomes in metastatic RCC. In addition, there is an added nuance of analyzing the role of CN in the presence of contemporary immune checkpoint combination therapy. There is preclinical evidence that suggests that the immune checkpoint inhibitors would be primed to demonstrate improved efficacy in the presence of the primary tumor. Randomized trials of systemic therapy with immune checkpoint inhibition with or without CN are being planned in this setting.

We attempted to evaluate the magnitude of the problem by assessing the incidence of CN in metastatic RCC within the SEER data. We analyzed the factors that are likely to impact the decision of CN in the initial management of advanced RCC. We explored demographic and disease-related factors. In addition, we assessed the impact of comorbidities in receipt of initial CN using additional data from the Metropolitan Detroit Cancer Surveillance System (MDCSS). We conducted an analysis of distant/metastatic cases of RCC within the SEER-18 data between 2000 and 2013. The intention was to evaluate the incidence of CN in the contemporary systemic therapy era and to assess the factors that impacted the decision of CN. We chose to explore the impact of a few key comorbidities such as renal function, hypertension, diabetes mellitus, and lung disease.

Methods {#sec2}
=======

The National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER-18) contains regional research data (1973--2011) submitted in November 2013 with the Katrina/Rita population adjustment, collected from 18 American cancer registries, chosen for their data quality and population diversity. The MDCSS is a data contributor to the SEER Program. Data for the primary analyses were extracted using SEER\*Stat software (version 8.3.1), for patients diagnosed with renal cancer between the years 2000 and 2013. We restricted the analysis to the first diagnosis of regional or distant stage kidney cancer, overall referred to as "metastatic" kidney cancer. Site-specific surgery codes 30, 40, 50, 70, or 80 were defined as having received nephrectomy. The main focus was advanced or metastatic cases with RCC which are coded as "distant" in SEER. Logistic regression analysis was used to calculate odds ratios (OR) of a patient who has undergone nephrectomy, adjusted for age at diagnosis, race, gender, marital status, insurance and disease histology, and grade. Cox proportional hazards regression analysis was used to calculate adjusted hazard ratios (HR) to estimate the overall risk of death. Hazard ratios were adjusted for nephrectomy as well as for all other variables listed above. Analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC). Patients with OS \< 1 month were excluded from the analysis with the assumption that any treatment would not have a chance to impact their outcomes. [Figure 1](#f0001){ref-type="fig"} depicts the flowchart of the patient population considered and selected for analysis.

![Consort diagram of patient population included in analyses.](JKCVHL-6-121-g001){#f0001}

We also performed a separate analysis using the same criteria for MDCSS data, extracted from the local SEER Database Management System (SEER\*DMS) using SAS© v 9.4, to evaluate the influence of comorbidities, as these data are not collected by SEER. Logistic regression was used to calculate the odds ratios for receiving CN. Hazard ratios were calculated using Cox proportional hazards regression.

Results {#sec3}
=======

Overview and predictors of nephrectomy {#sec3.1}
--------------------------------------

After exclusion of renal pelvis cases, final SEER-18 data for 2000--2013 had N = 40,524 patients. Case distribution by stage included regional stage (N = 19,472, 48%, 93% had nephrectomy) and distant stage (N = 21,052, 52%, 37% had nephrectomy). Our analyses were restricted to distant or metastatic stage patients only ([Figure 1](#f0001){ref-type="fig"}). The population characteristics of all SEER registry "regional" and "distant cases" are depicted in [Table 1](#t0001){ref-type="table"}.

###### 

Population Characteristics and Nephrectomy Rates of All SEER Kidney Cancer, Regional or Distant Stage: 2000--2013.

                                        Regional 18,837   Distant 18,422                      
  ------------------------------------- ----------------- ---------------- ---- -------- ---- -----
  **Registry**                                                                                
  Alaska                                22                0                91   28       0    32
  Atlanta                               540               3                92   558      3    41
  California (excl SF,SJM, & LA)        4196              22               94   4195     23   43
  Connecticut                           869               5                93   794      4    37
  Detroit                               939               5                93   947      5    39
  Georgia (greater)                     1381              7                92   1307     7    39
  Hawaii                                356               2                98   276      1    45
  Iowa                                  896               5                96   921      5    43
  Kentucky                              1234              7                94   1184     6    43
  Los Angeles                           1845              10               95   1830     10   45
  Louisiana                             1370              7                91   1334     7    38
  New Jersey                            1985              11               94   1849     10   41
  New Mexico                            538               3                91   522      3    33
  Rural Georgia                         32                0                97   37       0    35
  San Francisco                         779               4                93   848      5    45
  San Jose                              421               2                95   448      2    43
  Seattle                               977               5                94   980      5    42
  Utah                                  457               2                95   364      2    50
  **Age at diagnosis (year)**                                                                 
  Under 20                              626               3                98   502      3    91
  20--39                                577               3                96   452      2    55
  40--49                                1937              10               97   1855     10   56
  50--59                                4422              23               97   4511     24   51
  60--69                                5369              29               95   5184     28   42
  70--79                                4122              22               93   3762     20   31
  80 or older                           1784              9                78   2156     12   12
  **Sex**                                                                                     
  Female                                6280              33               92   6185     34   39
  Male                                  12,557            67               95   12,237   66   43
  **Race**                                                                                    
  Black                                 1612              9                90   1926     10   35
  White                                 16,020            85               94   15,241   83   42
  Other                                 1102              6                96   1208     7    44
  Unknown                               103               1                98   47       0    40
  **Marital status**                                                                          
  Married                               11,556            61               96   10,482   57   46
  Divorced                              1700              9                92   1994     11   39
  Single                                2959              16               95   3077     17   45
  Widowed                               1890              10               85   2230     12   22
  Unknown                               732               4                85   639      3    33
  **Insurance**                                                                               
  Insured                               8449              45               95   7573     41   43
  Uninsured/medicaid                    1530              8                93   1887     10   36
  Unknown/missing                       8858              47               93   8962     49   41
  **Histology**                                                                               
  Clear cell                            14,287            76               94   13,952   76   39
  Renal cell carcinoma, Chromophobe     662               4                98   125      1    76
  Renal cell carcinoma, Sarcomatoid     488               3                95   878      5    62
  Collecting duct carcinoma             90                0                94   98       1    67
  Papillary carcinoma, Oxyphilic cell   0                 0                \-   1        0    100
  Other non-clear cell                  3310              18               93   3368     18   46
  **Grade**                                                                                   
  Well differentiated                   859               5                97   318      2    45
  Moderately differentiated             5513              29               99   1750     9    71
  Poorly differentiated                 5902              31               98   3653     20   73
  Undifferentiated                      2319              12               98   2233     12   86
  Unknown                               4244              23               78   10,468   57   16
  **Surgery**                                                                                 
  Nephrectomy                           17,665            94                    7660     42   
  Other surgery                         142               1                     179      1    
  No urgery                             1016              5                     10,500   57   
  Unknown if Surgery done               14                0                     83       0    

Nephr Rate, nephrectomy rate.

Adjusted predictors of statistically increased likelihood of receiving nephrectomy were age (≤63 years), male sex (white race), and marital status. An interaction effect was noted between gender and marital status with married males having a significantly higher nephrectomy rate (42%) than divorced, single, and widowed men (35, 38, and 18% respectively). Single males were significantly less likely to receive nephrectomy than females (OR 0.53, 95% confidence interval \[CI\] 0.44--0.64). Single females had the highest (44%) likelihood of nephrectomy. Non-clear cell histology and poorly differentiated grade had a higher possibility of receiving CN as compared to clear cell histology and well-differentiated cancer, respectively ([Table 2](#t0002){ref-type="table"}).

###### 

All SEER Distant Stage Kidney Cancer: 2000--2013; Odd Ratios for Likelihood of Nephrectomy.

  Total                                          N 18422   Nephr. Rate 42 (%)   Unadjusted OR   Adjusted OR               95% CI         *p-value*
  ---------------------------------------------- --------- -------------------- --------------- ------------------------- -------------- -----------
  **Age at Diagnosis Diagnosis *(median 63)***                                                                                           
  (ref) Under 63                                 8982      53                   1.00            1.00                                     
  63 or Older                                    9440      31                   0.39            0.41                      (0.38--0.44)   *\<0.001*
  **Race *(47 missing)***                                                                                                                
  (ref) Black                                    1926      35                   1.00            1.00                                     
  White                                          15241     42                   1.34            1.51                      (1.33--1.72)   *\<0.001*
  Other                                          1208      44                   1.43            1.52                      (1.25--1.84)   *\<0.001*
  Unknown                                        47        40                                   N/A                                      
  **Insurance**                                                                                                                          
  (ref) Insured                                  7573      43                   1.00            1.00                                     
  Medicaid or Uninsured                          1887      36                   0.75            0.65                      (0.57--0.75)   *\<0.001*
  Unknown or Missing                             8962      41                   0.93            1.17                      (1.08--1.27)   *\<0.001*
  **Histology**                                                                                                                          
  (ref) Clear Cell                               13952     39                   1.00            1.00                                     
  Non-Clear Cell                                 4470      50                   1.59            1.58                      (1.45--1.73)   *\<0.001*
  **Grade**                                                                                                                              
  (ref) Well differentiated                      318       45                   1.00            1.00                                     
  Moderately differentiated                      1750      71                   3.06            3.35                      (2.59--4.33)   *\<0 001*
  Poorly differentiated                          3653      73                   3.32            3.24                      (2.53--4.13)   *\<0 001*
  Undifferentiated                               2233      86                   7.54            7.15                      (5.49--9.31)   *\<0 001*
  Unknown                                        10468     16                   0.24            0.23                      (0.18--0.29)   *\<0 001*
  **Sex**                                                                                                                                
  (ref) Female                                   6185      39                   1.00            *See interaction below*                  
  Male                                           12237     43                   1.16                                                     
  **Marital Status**                                                                                                                     
  (ref) Married                                  10482     46                   1.00            *See interaction below*                  
  Divorced                                       1994      39                   0.75                                                     
  Single                                         3077      45                   0.96                                                     
  Widowed                                        2230      22                   0.34                                                     
  Unknown                                        639       33                   0.58                                                     
  **Sex by Marital Status**                                                                                                              
  Male                                           7767      46                   1.00            1.03                      (0.92--1.16)   *0.567*
  Divorced                                                                                                                               
  (ref) Female                                   742       40                   1.00            1.00                                     
  Male                                           1252      38                   0.93            0.79                      (0.62--1.00)   *0.047*
  Single                                                                                                                                 
  (ref) Female                                   984       49                   1.00            1.00                                     
  Male                                           2093      43                   0.76            0.53                      (0.44--0.64)   *\<0.001*
  Widowed                                                                                                                                
  (ref) Female                                   1528      22                   1.00            1.00                                     
  Male                                           702       23                   1.03            1.03                      (0.79--1.34)   *0.963*
  Unknown                                                                                                                                
  (ref) Female                                   216       28                   1.00            1.00                                     
  Male                                           423       35                   1.43            1.33                      (0.84--2.09)   *0.298*
  Married                                                                                                                                
  (ref) Female                                   2715      46                   1.00            1.00                                     

Italic values represent missing data.

Survival status {#sec3.2}
---------------

Receipt of nephrectomy demonstrated significant survival advantage (HR = 0.31, 95% CI: 0.30--0.33) in the adjusted hazards ratio model. Median OS was 3 months in the non-CN group and 18 months in the CN group ([Table 3](#t0003){ref-type="table"} and [Figure 2A](#f0002){ref-type="fig"}). The demographic predictors of improved survival were age [\<]{.ul}63, white race, married status, and insured status ([Table 3](#t0003){ref-type="table"}). Clear cell histology (HR = 1.20, 95% CI: 1.16--1.24) and well-differentiated grade are the disease-related characteristics that portend for improved OS ([Figure 2B](#f0002){ref-type="fig"}). The latter demonstrated improved OS despite a lower, 43% CN rate as compared to 84% in the undifferentiated histology group. The histology grades in SEER of well, moderate, poor, and undifferentiated RCC are likely to be concordant with the conventional Fuhrman 1--4 grading ([Table 3](#t0003){ref-type="table"}).

###### 

All SEER Distant Stage Kidney Cancer (2000--2013) Survival Analysis (Median Survival, Adjusted Hazard Ratio, 95% Confidence Interval, and P-value).

  Total                                N 18422   Median Survival *(months)*   HR   95% CI   *p-value*      
  ------------------------------------ --------- ---------------------------- ---- -------- -------------- -----------
  **Age at Diagnosis *(median 63)***                                                                       
  (ref) Under 63                       8982      20                           25   1.00                    
  63 or Older                          9440      16                           4    1.16     (1.12--1.20)   *\<0.001*
  **Sex**                                                                                                  
  (ref) Female                         6185      18                           4    1.00                    
  Male                                 12237     19                           5    0.99     (0.96--1.03)   *0.702*
  **Race *(47 missing)***                                                                                  
  (ref) Black                          1926      16                           4    1.00                    
  White                                15241     25                           5    0.98     (0.93--1.02)   *0.342*
  Other                                1208      18                           5    0.88     (0.81--0.95)   *0.002*
  **Marital Status**                                                                                       
  (ref) Married                        10482     17                           5    1.00                    
  Divorced                             1994      16                           5    1.05     (1.00--1.11)   *0.051*
  Single                               3077      29                           5    0.86     (0.82--0.90)   *\<0.001*
  Widowed                              2230      14                           4    1.09     (1.04--1.15)   *0.001*
  Unknown                              639       20                           5    0.86     (0.79--0.94)   *0.001*
  **Insurance**                                                                                            
  (ref) Insured                        7573      20                           5    1.00                    
  Medicaid or Uninsured                1887      21                           5    1.03     (0.97--1.09)   *0.427*
  Unknown or Missing                   8962      16                           4    1.16     (1.12--1.20)   *0.001*
  **Histology**                                                                                            
  (ref) Clear Cell                     13952     20                           5    1.00                    
  Non-Clear Cell                       4470      13                           4    1.16     (1.12--1.21)   *\<0.001*
  **Grade**                                                                                                
  (ref) Well differentiated            318       35                           9    1.00                    
  Moderately differentiated            1750      30                           6    1.30     (1.13--1.49)   *\<0.001*
  Poorly differentiated                3653      18                           4    1.86     (1.63--2.13)   *\<0.001*
  Undifferentiated                     2233      11                           3    2.47     (2.16--2.83)   *\<0.001*
  Unknown                              10468     26                           5    1.48     (1.30--1.69)   *\<0.001*
  **Surgery**                                                                                              
  No Nephrectomy                       10762     \-                           5    1.00                    
  Nephrectomy                          7660      18                           \-   0.34     (0.32--0.35)   *\<0.001*

95% CI, 95% confidence interval; HR, hazard ratio; Nephr, nephrectomy.

![(A) Overall survival data for nephrectomy or non-nephrectomy patients with advanced kidney cancer in SEER database. (B) Overall survival outcomes in metastatic RCC by clear and non-clear histology with or without nephrectomy.](JKCVHL-6-121-g002){#f0002}

Comorbidity analyses in Metro Detroit Registry {#sec3.3}
----------------------------------------------

The data regarding comorbid conditions were only available for the Metro Detroit (MDCSS) Registry. While not collected as a population-based variable, comorbidity status was coded for 82% of regional and 76% of metastatic kidney cancers seen in Metropolitan Detroit. Nephrectomy was performed in 92% of regional stage and 34% of distant stage patients; our analysis pertains to only the distant-stage patients. Dichotomous comorbidities (yes or no for: hypertension, cardiac disease, diabetes mellitus, kidney disease, and lung disease) and number of comorbid conditions (none, 1, 2, 3+, and missing) are included in the patient characteristics of MDSCC ([Table 4](#t0004){ref-type="table"}). The demographic and tumor characteristics were concordant with the all SEER data; 44.9% of the patients had none of the comorbidities. Adjusted demographic predictors of increased likelihood of receiving nephrectomy for Metropolitan Detroit patients were age \< 64 years, non-black race, and married status. Non-clear cell histology (OR = 2.16, 95% CI: 1.42--3.28) and undifferentiated or high also predicted a higher likelihood of CN. Adding comorbidities and number of comorbidities to the model did not impact the likelihood of receiving nephrectomy. All comorbidity types and numbers were not statistically significant in terms of predicting the likelihood of CN and OS ([Table 5](#t0005){ref-type="table"}). Patients with hypertension (OR = 1.75, 95% CI: 0.63--4.87) or diabetes mellitus had greater likelihood of receiving nephrectomy (OR = 1.16, 95% CI: 0.42, 3.21). The group of patients with missing comorbidity data (261/1104, 23.6%) had a significantly shorter OS in both CN and non-CN categories. The actual correlation of comorbidities with likelihood of CN remains elusive due to the group with missing data constituting 24% of the population; 26% of this group had a nephrectomy and demonstrated a median OS of 8 months as compared to the 76% with a median OS of 2 months ([Tables 4](#t0004){ref-type="table"} and [5](#t0005){ref-type="table"}; [Figure 3A](#f0003){ref-type="fig"} and [3B](#f0003){ref-type="fig"}).

###### 

Metropolitan Detroit Distant Stage Kidney Cancer: 2000--2013 Odd Ratios for Likelihood of Nephrectomy.

  Total                                N 1008   Distribution   Nephr. Rate 37 (%)   Adjusted OR                                                       95% CI         *p-value*
  ------------------------------------ -------- -------------- -------------------- ----------------------------------------------------------------- -------------- -----------
  **Age at Diagnosis *(median 64)***                                                                                                                                 
  (ref) Under 64                       498      49             51                   1.00                                                                             
  64 or Older                          510      51             23                   0.29                                                              (0.21--0.39)   *\<0.001*
  **Sex**                                                                                                                                                            
  (ref) Female                         338      34             36                   1.00                                                                             
  Male                                 670      66             37                   0.87                                                              (0.64--1.19)   *0.389*
  **Race**                                                                                                                                                           
  (ref) Black                          206      20             34                   1.00                                                                             
  White                                788      78             38                   1.48                                                              (1.03--2.13)   *0.035*
  Other                                14       1              36                   \-                                                                               
  **Marital Status**                                                                                                                                                 
  (ref) Married                        507      50             40                   1.00                                                                             
  Divorced                             118      12             31                   0.60                                                              (0.38--0.95)   *0.031*
  Single                               202      20             43                   0.81                                                              (0.56--1.19)   *0.285*
  Widowed                              146      14             21                   0.51                                                              (0.31--0.83)   *0.006*
  Unknown                              35       3              37                   1.13                                                              (0.52--2.44)   *0.757*
  **Insurance**                                                                                                                                                      
  (ref) Insured                        663      66             38                   1.00                                                                             
  Medicaid or Uninsured                277      27             40                   1.12                                                              (0.79--1.59)   *0.524*
  Unknown or Missing                   67       7              18                   0.41                                                              (0.21--0.81)   *0.010*
  **Histology**                                                                                                                                                      
  (ref) Clear Cell                     695      69             34                   1.00                                                                             
  Non-Clear Cell                       313      31             45                   1.68                                                              (1.25--2.27)   *0.001*
  **Grade**                                                                                                                                                          
  (ref) Well or Mod Diff               75       7              44                   *left out of model because of the large proportion of unknowns*                  
  Poorly Diff                          168      17             70                                                                                                    
  Undifferentiated                     152      15             81                                                                                                    
  Unknown                              613      61             16                                                                                                    
  **Number of Comorbid conditions**                                                                                                                                  
  (ref) None of the above              465      46             36                   1.00                                                                             
  One                                  165      16             41                   1.25                                                              (0.84--1.87)   *0.269*
  Two or more                          156      15             46                   1.76                                                              (1.17--2.66)   *0.007*
  Missing data                         222      22             31                   0.80                                                              (0.54--1.18)   *0.249*

95% CI, 95% confidence interval; Mod Diff, moderately differentiated.

###### 

Metropolitan Detroit Distant Stage Kidney Cancer: 2000--2013 Survival Analysis by Nephrectomy Status for Demographic Characteristics and Comorbidities.

  Total                                N 1008   Median Survival *(months)*   HR   95% CI                                                            *p-value*      
  ------------------------------------ -------- ---------------------------- ---- ----------------------------------------------------------------- -------------- -----------
  **Age at Diagnosis *(median 64)***                                                                                                                               
  (ref) Under 64                       551      22                           5    1.00                                                                             
  64 or Older                          553      15                           5    1.08                                                              (0.93--1.25)   *0.335*
  **Sex**                                                                                                                                                          
  (ref) Female                         370      19                                1.00                                                                             
  Male                                 734      20                                1.00                                                              (0.86--1.16)   *0.990*
  **Race *(55 missing)***                                                                                                                                          
  (ref) Black                          232      30                           4    1.00                                                                             
  White                                857      18                           5    1.02                                                              (0.86--1.21)   *0.824*
  Other                                15       \-                           \-   \-                                                                               
  **Marital Status**                                                                                                                                               
  (ref) Married                        552      18                           5    1.00                                                                             
  Divorced                             122      12                           4    1.18                                                              (0.95--1.46)   *0.145*
  Single                               222      43                           4    0.76                                                              (0.62--0.93)   *0.007*
  Widowed                              169      17                           4    1.02                                                              (0.82--1.25)   *0.891*
  Unknown                              39       16                           8    0.71                                                              (0.49--1.02)   *0.064*
  **Insurance**                                                                                                                                                    
  (ref) Insured                        720      18                           5    1.00                                                                             
  Medicaid or Uninsured                309      22                           4    1.02                                                              (0.86--1.22)   *0.784*
  Unknown or Missing                   75       31                           4    1.35                                                              (1.03--1.78)   *0.032*
  **Histology**                                                                                                                                                    
  (ref) Clear Cell                     755      20                           5    1.00                                                                             
  Non-Clear Cell                       349      18.5                         4    1.17                                                              (1.01--1.36)   *0.037*
  **Grade**                                                                                                                                                        
  (ref) Well or Mod Diff               76       35                           9    *left out of model because of the large proportion of unknowns*                  
  Poorly Diff                          178      19                           4                                                                                     
  Undifferentiated                     158      12                           3                                                                                     
  Unknown                              692      36                           5                                                                                     
  **Surgery**                                                                                                                                                      
  No Nephrectomy                       726      \-                           3    1.00                                                                             
  Nephrectomy                          378      19                           \-   0.40                                                              (0.34--0.46)   *\<0.001*
  **Number of Comorbid conditions**                                                                                                                                
  (ref) None of the above              496      24                           5    1.00                                                                             
  One                                  178      24                           4    1.12                                                              (0.92--1.36)   *0.275*
  Two or more                          169      18                           5    1.10                                                              (0.90--1.35)   *0.370*
  Missing data                         261      8.5                          4    1.68                                                              (1.39--2.01)   *\<0.001*

95% CI, 95% confidence interval; Mod Diff, moderately differentiated; Nephr, nephrectomy.

![(A) Overall survival noted in cases with nephrectomy correlated with missing, absence, and presence of comorbidities. (B) Overall survival seen in cases with no nephrectomy correlated with missing, absence, and presence of comorbidities.](JKCVHL-6-121-g003){#f0003}

Discussion {#sec4}
==========

Our analysis reveals that CN is not being conducted in the majority of patients that present with synchronous metastatic RCC. There is a tremendous discordance between the population of advanced RCC enrolled in prospective interventional clinical trials in which 80--90% of the patients have had nephrectomy, and the application of these reported efficacy data to clinical practice in which the majority of patients do not undergo CN. There is a discrepancy between the results of retrospective population-based data such as the SEER cancer registry outcomes data and the IMDC registry data in which OS is significantly better with CN, and those seen in prospective randomized trial results such as the CARMENA and SURTIME studies that show that CN is unlikely to make an impact on improving outcomes in the setting of contemporary anti-VEGF therapy such as sunitinib ([@cit0009]). SEER data consistently demonstrate that lack of CN is the largest contributor of shorter OS in RCC patients with distant-stage RCC. The factors included within the IMDC are not captured within the SEER database, and hence, comparison of patients within these different registries is not possible. However, it is highly likely that the extent of the impact of each factor on OS may not be equal, and interaction between the factors is likely. In addition, it is possible that synchronous presentation of primary kidney tumor and metastases represents a distinct disease entity than the presentation with metastatic disease following a remote history of nephrectomy (\>12 months) for localized renal cancer.

The advent of immune therapy with checkpoint inhibitors has introduced a new perspective to the sequencing of CN and systemic therapy in metastatic RCC. Preclinical data continue to emerge supporting the optimal use of immune checkpoint inhibition with the primary tumor in place, due to higher mutation load, increased heterogeneity of mutations and greater potential for anti-tumor CD8 T cells expansion and cytokine release ([@cit0010], 11). These findings demand a deeper evaluation of the established paradigm of initial CN in metastatic RCC followed by systemic therapy. In fact, this standard is already being questioned in localized RCC by the current cooperative group trial EA8143/PROSPER, which randomizes patients to standard therapy of CN or neoadjuvant PD-1 inhibitor therapy with nivolumab followed by CN. In the metastatic disease also, deferral of nephrectomy as a potential method of enhancing the efficacy of immune checkpoint inhibition needs to be prospectively evaluated. SEER-18 limited use data do not include systemic agents, and this was a limitation of our analysis. A Southwest Oncology Group trial, S1931, is proposing to evaluate immune checkpoint inhibitor-based regimen combination with or without the addition of CN. The timing of surgery in the nephrectomy arm will be at the end of 12 weeks of immune therapy to optimize the impact of systemic therapy. The study design is that of a randomized phase III with overall survival as the primary endpoint.

Conclusions {#sec5}
===========

National population registry represented by the SEER database shows that the majority of patients (63%) with metastatic RCC do not undergo CN. Nephrectomy still represents a significant factor that predicts for improved OS outcome in advanced RCC within population databases such as SEER and NCDB. Median OS of 3 months in the non-CN group and that of 18 months for cases with CN suggests the large magnitude of the disparity. Patient demographics and tumor characteristics make a significant impact on the incidence of CN. The impact of comorbidities (number and type) appeared to be modest within the population represented in the Metropolitan Detroit SEER data and was not statistically significant. The optimal management strategy of patients with advanced RCC unable to undergo nephrectomy needs to be prospectively evaluated in future clinical trials, in the setting of contemporary systemic therapy.

The subgroup of synchronous primary and metastatic kidney cancer has been underrepresented in clinical trials. Future studies geared toward addressing the issues of optimal efficacy of therapy within this patient population are being planned. Patient and disease characteristics that determine decision of CN warrant further study and may represent a key to the enhancement of outcomes in advanced renal cancer.
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